Switch theme
Sign up to access all valuation multiples
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.
2011
33
LTM Revenue n/a
LTM EBITDA n/a
$107M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Eupraxia Pharmaceuticals has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Eupraxia Pharmaceuticals achieved revenue of n/a and an EBITDA of -$17.5M.
Eupraxia Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Eupraxia Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$19.3M | -$17.5M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$12.0M | -$19.7M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Eupraxia Pharmaceuticals's stock price is CAD 4 (or $3).
Eupraxia Pharmaceuticals has current market cap of CAD 154M (or $108M), and EV of CAD 152M (or $107M).
See Eupraxia Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $107M | $108M | XXX | XXX | XXX | XXX | $-0.70 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Eupraxia Pharmaceuticals has market cap of $108M and EV of $107M.
Eupraxia Pharmaceuticals's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Eupraxia Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Eupraxia Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $107M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -6.1x | XXX | XXX | XXX |
| P/E | -6.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -5.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpEupraxia Pharmaceuticals's NTM/LTM revenue growth is Infinity%
Eupraxia Pharmaceuticals's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.6M for the same period.
Over next 12 months, Eupraxia Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Eupraxia Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Eupraxia Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -10% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.6M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Eupraxia Pharmaceuticals acquired XXX companies to date.
Last acquisition by Eupraxia Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Eupraxia Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Eupraxia Pharmaceuticals founded? | Eupraxia Pharmaceuticals was founded in 2011. |
| Where is Eupraxia Pharmaceuticals headquartered? | Eupraxia Pharmaceuticals is headquartered in Canada. |
| How many employees does Eupraxia Pharmaceuticals have? | As of today, Eupraxia Pharmaceuticals has 33 employees. |
| Who is the CEO of Eupraxia Pharmaceuticals? | Eupraxia Pharmaceuticals's CEO is Dr. James A. Helliwell, M.D.. |
| Is Eupraxia Pharmaceuticals publicy listed? | Yes, Eupraxia Pharmaceuticals is a public company listed on TSE. |
| What is the stock symbol of Eupraxia Pharmaceuticals? | Eupraxia Pharmaceuticals trades under EPRX ticker. |
| When did Eupraxia Pharmaceuticals go public? | Eupraxia Pharmaceuticals went public in 2021. |
| Who are competitors of Eupraxia Pharmaceuticals? | Similar companies to Eupraxia Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Eupraxia Pharmaceuticals? | Eupraxia Pharmaceuticals's current market cap is $108M |
| Is Eupraxia Pharmaceuticals profitable? | Yes, Eupraxia Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
